John H Stroger Hospital Of Cook County
Chicago, Illinois, 60612, United States
NCT Number: NCT00732524
The purpose of this study is to compare two simple and safe emergency department discharge therapy for Type 2 Diabetes patients with severe hyperglycemia and with no indications for inpatient admission.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Phase 4
Chicago, Illinois, 60612, United States
This study is an open label randomized controlled trial in adult DM2 patients seen in ED services at John H. Stroger Hospital of Cook County serving a largely uninsured/underserved population. Individuals more than 18 years of age with DM2, either with new onset DM2 or known diabetics who did not take oral hypoglycemic agents for more than 2 weeks, presenting with fasting blood glucose (FBG) 300-500 mg/dl or random blood glucose (RBG) 400-700 mg/dl and who did not have any exclusion criteria listed in Table 1, were eligible for the study. Subjects were randomized to one of the two fixed dose treatment groups: 1) Glipizide XL 10 mg orally daily prior to breakfast (G group), 2) Glipizide XL 10 mg orally daily along with Insulin Glargine 10 units at bedtime, subcutaneously (G+G group).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Glipizide XL 10 mg once daily 30 mins before breakfast
Other names: Glucotrol XL
Glipizide XL 10 mg daily 30 minutes before breakfast Insulin Glargine 10 units subcutaneously at bedtime daily
Other names: Insulin Lantus
Time frame: 2 months
Time frame: 2 months
Cook County Health
Other Gov
Combination of Sulfonylureas and Insulin Glargine as Safety Net Outpatient Therapy for Unstable Diabetes and Impending Diabetic Ketoacidosis (DKA)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06899191
Autoimmune Diseases, Diabetes Mellitus
New Brunswick, New Jersey, United States
View Trial DetailsNCT07147010
Diabetes Mellitus, Diabetes Mellitus, Type 2
Bern, Switzerland
View Trial DetailsNCT06016478
Diabetes Mellitus, Diabetes Mellitus, Type 2
Lubbock, Texas, United States
View Trial DetailsNCT05550870
Diabetes Mellitus, Diabetes Mellitus, Type 2
Lahore, Punjab Province, Pakistan
View Trial Details